2026 Q1 -tulosraportti
1 päivä sitten
‧29 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 216 | - | - | ||
| 5 | - | - | ||
| 5 000 | - | - | ||
| 455 | - | - | ||
| 1 805 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 185 298 | 185 298 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 185 298 | 185 298 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenThe price finally seems to be turning around, as there are green %-s for the last 6 months, but there is still room for improvement. 2.0 must be the next target this year.
·2 t sittenIt depends on when KDIGO comes out with a 1st degree recommendation for the NGAL test. Those of us who have kept the stock in our portfolio, and have bought at the bottom, we can just lean back and watch all those who only buy when the announcement is made public. Bioporto has announced that they have already acquired 4 new hospitals in Q1. The reason why these hospitals have already integrated the NGAL test in Q1 and not in Q4, (see CBs explanation in Webcast Q 4 2025) is due to KDIGO's draft and the various announcements before the hearing concluded. We know that FDA will approve the adult test, it's just a question of when.- ·21 t sittenKDIGO guidelines likely the next catalyst - Q1 review https://access.dnbcarnegie.com/publication/ef21af0f-6d31-42be-0550-08deb7025c09·51 min sitten · MuokattuKDIGO will issue a recommendation before the FDA approves the Test for adults. Once KDIGO's recommendations have been published, all treatment centers worldwide that are "affected" by the 1st degree recommendation will ensure that the NGAL test becomes part of routine treatment. Since CB touched upon this topic at the last webcast, he naturally couldn't be as direct as I am and have been. Despite CB very clearly stating that they had full focus on the USA. "ROW" will proactively ensure that the test is integrated into their treatment system, which is affected by the 1st degree recommendation.
·1 päivä sittenWhy has Bioporto perhaps chosen to deliver a "decimated" quarterly report, where many of the usual details are omitted? And why hasn't 3D commented yet? Has 3D perhaps not noticed it?·1 päivä sitten@Progression: Well, just that revenue increases while the loss decreases, and that is a good start to the year.·23 t sitten · MuokattuRevenue lands 6 % below the average quarterly sales in 2025. Has inflation been 4-5 % since 2025? Have sales on average fallen by 10 %? Is it the RSU sales that "drives" the business and not sales used in the healthcare sector? Is everything as it should be? The loss has become smaller vs Q1 25. Is there an explanation for the saving, has one sold fewer products at a higher price?- ·1 päivä sittenWatch or rewatch Webcast Q 1 https://www.youtube.com/watch?v=FRc-y2wEHOM·1 päivä sittenIt was a pleasure to hear the explanation that CB provided about KDIGO, because the analyses that I have arrived at, about KDIGO, and what it means for Bioporto, lean closely on what CB stated. The next thing I am excited about is whether I am also right that there will be a 1st degree recommendation for the critical areas, and a 2nd degree recommendation for other areas. (It is not unthinkable that there will be more recommendations than the two, so that it becomes as detailed as possible)
- ·2 päivää sittenA reminder There is a webcast tomorrow at 11 AM. Registration required https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2026-resultater·1 päivä sittenBioporto's top line grows with progress in the USA in the first quarter https://medwatch.dk/brancher/diagnostik/article19316772.ece
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
1 päivä sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenThe price finally seems to be turning around, as there are green %-s for the last 6 months, but there is still room for improvement. 2.0 must be the next target this year.·2 t sittenIt depends on when KDIGO comes out with a 1st degree recommendation for the NGAL test. Those of us who have kept the stock in our portfolio, and have bought at the bottom, we can just lean back and watch all those who only buy when the announcement is made public. Bioporto has announced that they have already acquired 4 new hospitals in Q1. The reason why these hospitals have already integrated the NGAL test in Q1 and not in Q4, (see CBs explanation in Webcast Q 4 2025) is due to KDIGO's draft and the various announcements before the hearing concluded. We know that FDA will approve the adult test, it's just a question of when.
- ·21 t sittenKDIGO guidelines likely the next catalyst - Q1 review https://access.dnbcarnegie.com/publication/ef21af0f-6d31-42be-0550-08deb7025c09·51 min sitten · MuokattuKDIGO will issue a recommendation before the FDA approves the Test for adults. Once KDIGO's recommendations have been published, all treatment centers worldwide that are "affected" by the 1st degree recommendation will ensure that the NGAL test becomes part of routine treatment. Since CB touched upon this topic at the last webcast, he naturally couldn't be as direct as I am and have been. Despite CB very clearly stating that they had full focus on the USA. "ROW" will proactively ensure that the test is integrated into their treatment system, which is affected by the 1st degree recommendation.
- ·1 päivä sittenWhy has Bioporto perhaps chosen to deliver a "decimated" quarterly report, where many of the usual details are omitted? And why hasn't 3D commented yet? Has 3D perhaps not noticed it?·1 päivä sitten@Progression: Well, just that revenue increases while the loss decreases, and that is a good start to the year.·23 t sitten · MuokattuRevenue lands 6 % below the average quarterly sales in 2025. Has inflation been 4-5 % since 2025? Have sales on average fallen by 10 %? Is it the RSU sales that "drives" the business and not sales used in the healthcare sector? Is everything as it should be? The loss has become smaller vs Q1 25. Is there an explanation for the saving, has one sold fewer products at a higher price?
- ·1 päivä sittenWatch or rewatch Webcast Q 1 https://www.youtube.com/watch?v=FRc-y2wEHOM·1 päivä sittenIt was a pleasure to hear the explanation that CB provided about KDIGO, because the analyses that I have arrived at, about KDIGO, and what it means for Bioporto, lean closely on what CB stated. The next thing I am excited about is whether I am also right that there will be a 1st degree recommendation for the critical areas, and a 2nd degree recommendation for other areas. (It is not unthinkable that there will be more recommendations than the two, so that it becomes as detailed as possible)
- ·2 päivää sittenA reminder There is a webcast tomorrow at 11 AM. Registration required https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2026-resultater·1 päivä sittenBioporto's top line grows with progress in the USA in the first quarter https://medwatch.dk/brancher/diagnostik/article19316772.ece
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 216 | - | - | ||
| 5 | - | - | ||
| 5 000 | - | - | ||
| 455 | - | - | ||
| 1 805 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 185 298 | 185 298 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 185 298 | 185 298 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
1 päivä sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenThe price finally seems to be turning around, as there are green %-s for the last 6 months, but there is still room for improvement. 2.0 must be the next target this year.·2 t sittenIt depends on when KDIGO comes out with a 1st degree recommendation for the NGAL test. Those of us who have kept the stock in our portfolio, and have bought at the bottom, we can just lean back and watch all those who only buy when the announcement is made public. Bioporto has announced that they have already acquired 4 new hospitals in Q1. The reason why these hospitals have already integrated the NGAL test in Q1 and not in Q4, (see CBs explanation in Webcast Q 4 2025) is due to KDIGO's draft and the various announcements before the hearing concluded. We know that FDA will approve the adult test, it's just a question of when.
- ·21 t sittenKDIGO guidelines likely the next catalyst - Q1 review https://access.dnbcarnegie.com/publication/ef21af0f-6d31-42be-0550-08deb7025c09·51 min sitten · MuokattuKDIGO will issue a recommendation before the FDA approves the Test for adults. Once KDIGO's recommendations have been published, all treatment centers worldwide that are "affected" by the 1st degree recommendation will ensure that the NGAL test becomes part of routine treatment. Since CB touched upon this topic at the last webcast, he naturally couldn't be as direct as I am and have been. Despite CB very clearly stating that they had full focus on the USA. "ROW" will proactively ensure that the test is integrated into their treatment system, which is affected by the 1st degree recommendation.
- ·1 päivä sittenWhy has Bioporto perhaps chosen to deliver a "decimated" quarterly report, where many of the usual details are omitted? And why hasn't 3D commented yet? Has 3D perhaps not noticed it?·1 päivä sitten@Progression: Well, just that revenue increases while the loss decreases, and that is a good start to the year.·23 t sitten · MuokattuRevenue lands 6 % below the average quarterly sales in 2025. Has inflation been 4-5 % since 2025? Have sales on average fallen by 10 %? Is it the RSU sales that "drives" the business and not sales used in the healthcare sector? Is everything as it should be? The loss has become smaller vs Q1 25. Is there an explanation for the saving, has one sold fewer products at a higher price?
- ·1 päivä sittenWatch or rewatch Webcast Q 1 https://www.youtube.com/watch?v=FRc-y2wEHOM·1 päivä sittenIt was a pleasure to hear the explanation that CB provided about KDIGO, because the analyses that I have arrived at, about KDIGO, and what it means for Bioporto, lean closely on what CB stated. The next thing I am excited about is whether I am also right that there will be a 1st degree recommendation for the critical areas, and a 2nd degree recommendation for other areas. (It is not unthinkable that there will be more recommendations than the two, so that it becomes as detailed as possible)
- ·2 päivää sittenA reminder There is a webcast tomorrow at 11 AM. Registration required https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2026-resultater·1 päivä sittenBioporto's top line grows with progress in the USA in the first quarter https://medwatch.dk/brancher/diagnostik/article19316772.ece
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 216 | - | - | ||
| 5 | - | - | ||
| 5 000 | - | - | ||
| 455 | - | - | ||
| 1 805 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 185 298 | 185 298 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 185 298 | 185 298 | 0 | 0 |